Next Article in Journal
Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Glioblastoma
Next Article in Special Issue
The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status
Previous Article in Journal
The Impact of Normalization Approaches to Automatically Detect Radiogenomic Phenotypes Characterizing Breast Cancer Receptors Status
Previous Article in Special Issue
Enhanced Expression of IGFBP-3 Reduces Radiosensitivity and Is Associated with Poor Prognosis in Oral Squamous Cell Carcinoma
Open AccessReview

Monitoring Immune Responses in Neuroblastoma Patients during Therapy

1
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands
2
Princess Máxima Center for Pediatric Oncology, Utrecht University, 3584 CS Utrecht, The Netherlands
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cancers 2020, 12(2), 519; https://doi.org/10.3390/cancers12020519
Received: 29 December 2019 / Revised: 14 February 2020 / Accepted: 18 February 2020 / Published: 24 February 2020
(This article belongs to the Special Issue Cancer Biomarkers)
Neuroblastoma (NBL) is the most common extracranial solid tumor in childhood. Despite intense treatment, children with this high-risk disease have a poor prognosis. Immunotherapy showed a significant improvement in event-free survival in high-risk NBL patients receiving chimeric anti-GD2 in combination with cytokines and isotretinoin after myeloablative consolidation therapy. However, response to immunotherapy varies widely, and often therapy is stopped due to severe toxicities. Objective markers that help to predict which patients will respond or develop toxicity to a certain treatment are lacking. Immunotherapy guided via immune monitoring protocols will help to identify responders as early as possible, to decipher the immune response at play, and to adjust or develop new treatment strategies. In this review, we summarize recent studies investigating frequency and phenotype of immune cells in NBL patients prior and during current treatment protocols and highlight how these findings are related to clinical outcome. In addition, we discuss potential targets to improve immunogenicity and strategies that may help to improve therapy efficacy. We conclude that immune monitoring during therapy of NBL patients is essential to identify predictive biomarkers to guide patients towards effective treatment, with limited toxicities and optimal quality of life. View Full-Text
Keywords: Neuroblastoma; biomarker; immunotherapy; anti-GD2; Dinutuximab; immune profiling; immune monitoring; adoptive cell therapy; checkpoint inhibitors; cytokines Neuroblastoma; biomarker; immunotherapy; anti-GD2; Dinutuximab; immune profiling; immune monitoring; adoptive cell therapy; checkpoint inhibitors; cytokines
Show Figures

Figure 1

MDPI and ACS Style

Szanto, C.L.; Cornel, A.M.; Vijver, S.V.; Nierkens, S. Monitoring Immune Responses in Neuroblastoma Patients during Therapy. Cancers 2020, 12, 519.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop